Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06870110 · ClinicalTrials.gov registry record · NA

Brain Training for Substance Use Disorders

A NA study of Opioid Use Disorder, sponsored by Neurotype.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06870110 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Neurotype. The registered enrollment target is 40 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06870110, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Neurotype.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.

Conditions Studied

Interventions

  • DEVICE Bias Modification Biofeedback

Study Locations (1)

Minnesota

  • University of Minnesota - Department of Psychiatry & Behavioral Health - Minneapolis

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-01-17
Est. Completion 2025-08-31
Phase NA

Sponsor

Neurotype

1 total trials

What the Registry Record Tells You About NCT06870110

The ClinicalTrials.gov registry entry for NCT06870110 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is Neurotype, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Bias Modification Biofeedback is the first listed.

NCT06870110 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06870110 about?

NCT06870110 is a clinical study titled "Brain Training for Substance Use Disorders". Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.

What is the current status of trial NCT06870110?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-01-17. Estimated completion is 2025-08-31.

What conditions does trial NCT06870110 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06870110?

The interventions under investigation include: Bias Modification Biofeedback (DEVICE).

Who is sponsoring clinical trial NCT06870110?

This trial is sponsored by Neurotype, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06870110 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.